/
Dual ART: Entering a New Paradigm Dual ART: Entering a New Paradigm

Dual ART: Entering a New Paradigm - PowerPoint Presentation

pamella-moone
pamella-moone . @pamella-moone
Follow
352 views
Uploaded On 2018-11-05

Dual ART: Entering a New Paradigm - PPT Presentation

Moderator François Raffi MD PhD Professor of Infectious and Tropical Diseases University of Nantes Nantes France Panelists Chloe Orkin MD FRCP Professor of HIV Medicine Grahame Hayton Unit ID: 716067

therapy dual art patients dual therapy patients art baseline treatment 2017 week regimen virologic eacs triple ritonavir hiv copies

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Dual ART: Entering a New Paradigm" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Dual ART: Entering a New Paradigm

Moderator

François Raffi, MD, PhD

Professor of Infectious and

Tropical Diseases

University of Nantes

Nantes, France Slide2

Panelists

Chloe Orkin, MD, FRCP

Professor of HIV Medicine

Grahame Hayton Unit

Royal London HospitalLondon, UK

José R. Arribas, MDResearch Director, HIV and Infectious Diseases Unit, Hospital La Paz, IdiPAZ; Associate Professor, Infectious Diseases, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain

Jürgen K. Rockstroh, MD

Professor of Medicine

Department of Internal Medicine I University Hospital Bonn

Bonn, GermanySlide3

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide4

Introduction to Dual ART

New data show that dual ART may be a viable strategy in patients meeting careful selection criteria

It may be used for toxicity sparing, cost reduction

Increased potency of some newer ARTs may allow for different therapy optionsSlide5

Raffi F, et al.

Lancet. 2014;384:1942-1951.

Dual ART With Raltegravir and Boosted

Darunavir in Treatment-Naive Patients: NEAT 001

NtRTI-sparing regimen was inferior to the standard regimen

in patients with baseline CD4 counts of less than 200 cells/μL and HIV-1 RNA concentrations higher than 100,000 copies/mL Slide6

Baril JG, et al.

PLoS One. 2016;11:e0148231.

Dual ART in Treatment-Naive Patients: Example of Miraviroc

Review of 16 studies of dual therapy regimens in the ART-naive population

Many underpowered to determine noninferiority to standard triple regimen

Study

Treatment Arm

HIV-1 RNA < 50

Copies/mL

A4001078

ATV/r

+

MVC

(n = 60)

48 wk: 74.6% (ITT)

96 wk: 67.8% (ITT)

ATV/r

+ TDF/FTC (n = 61)48 wk: 83.6% (ITT) 96 wk: 82.0% (ITT)MIDASDRV/r + MVC (N = 24)24 wk: 87.5%48 wk: 83.3%MODERNDRV/r + TDF/FTC (n = 406)48 wk: 86.8%DRV/r + MVC (n = 406)48 wk: 77.3%VEMANLPF/r + MVC (n = 26)48 wk: 100% (PP)LPV/r + TDF/FTC (n = 24)48 wk: 96% (PP)

Studies of Miraviroc as Dual ART

Combination of PI/ritonavir + integrase inhibitor raltegravir or NRTI lamivudine most definitive evidence for role of dual therapySlide7

Lambert-Niclot S, et al

. J Antimicrob Chemother. 2016;71:1056-1062.

Resistance-Associated Mutation in the NRTI-Sparing Regimen: NEAT 001/ANRS143 Trial

No RAM at virologic failure in the standard tenofovir/emtricitabine plus darunavir/ritonavir regimen

For the raltegravir plus darunavir/ritonavir NRTI-sparing regimen, RAM rate was 29.5% (mostly integrase mutations)Slide8

Cahn P, et al.

Lancet Infect Dis. 2014;14:572-580.

GARDEL Study: Noninferiority of Lopinavir/Ritonavir Plus Lamivudine

(n = 214 )

(n = 202 )

(n = 94 )

(n = 86 )

Difference 4.6%

(95% CI: -2.2, 11.8;

P

=.171)

Difference 9.3%

(95% CI: -2.8, 21.5;

P

=.145)

Patients With Viral Load <50 Copies/mL at 48 Weeks

Dual therapy with lopinavir and ritonavir plus lamivudine could be an effective first-line option for treatment-naive patientsSlide9

Dual Therapy as First-Line Treatment

Not currently recommended in guidelines

Studies have been small and more are needed

Evaluated efficacy, but some gaps in addressing safety issues

More data are available from treated patients in switching studies

Could consider the relevance of the point at which the virus replication cycle is inhibitedInhibition of reversed transcriptase may play an important role Slide10

Baril JG, et al.

PLoS One. 2016;11:e0148231.

Switching to Dual ART: Virologically Suppressed Patients

Earlier dual ART studies had not shown much success (eg, with maraviroc plus a PI)

Starting in 2015, increasing evidence that a well-chosen regimen could be effective

Eg, any boosted PI plus lamivudine has begun to achieve noninferiority to triple regimensSlide11

Orkin C, et al. EACS 2017. Poster BPD1/5.

Switching to Dual ART: SWORD-1 and -2

Study Design

Screening

Early-switch

phase

Late-switch phase

Continuation phase

Day 1

Week 52

Week 148

R

1:1

DTG

+ RPV

(n = 513)

CAR

(n = 511)

Viral load <50 copies/mL on INI, NNRTI, or PI + 2 NRTIsDTG + RPV

DTG

+ RPV

Primary endpoint at 48 weeks:

Participants with viral load <50 copies/mLSlide12

SWORD-1 and -2: Similar Virologic Outcomes for All Baseline Treatments

Orkin C, et al. EACS 2017. Poster BPD1/5.

DTG

+ RPV

(n

= 513)

CAR

(n = 511)

Virologic success

95

95

Virologic

non-response

<1

1

No virologic data

5

4

Overall Virologic Outcomes(HIV-1 RNA <50 copies/mL, %)DTG + RPV (n = 513)CAR (n = 511)PI9394NNRTI9695INSTI9495

Virologic Outcomes by Baseline ART Third-Agent Class(HIV-1 RNA <50 copies/mL, %)

Switching to dual therapy with dolutegravir and rilpivirine was noninferior to current antiretroviral regimen at 48 weeks, and virologic outcomes were similar for all baseline treatmentsSlide13

*

Bone resorption biomarker; †bone formation biomarker;

also used to calculate eGFR.

Orkin C, et al. EACS 2017. Poster BPD2/10.

SWORD-1 and -2 Secondary Endpoints: Renal, Inflammatory, and Bone BiomarkersAim was to evaluate the impact of dolutegravir plus rilpivirine on markers of bone turnover, renal function, atherogenesis, and inflammationSecondary study endpoints included change from baseline to week 48 for markers of bone turnover, renal function, atherogenesis, and inflammation

Biomarkers Evaluated

Bone Turnover

Renal Function

Mechanisms of

Atherogenesis

and Inflammation

Type-1 collagen C-telopeptide*

Osteocalcin

Procollagen 1-N-terminal propeptide

Bone-specific alkaline phosphatase

†Cystatin C‡RBPβ2MUrine phosphateCRPIL-6D-dimersCD163sCD14sVCAM-1 FABP2Slide14

Orkin C, et al. EACS 2017. Poster BPD2/10.

Decrease in Renal Biomarkers With Dual ART: SWORD-1/-2 Pooled Data

Greater decreases in RBP (urine) and β2M (urine) in the dolutegravir plus rilpivirine group

Greater decreases in RBP/creatinine ratio and β2M/creatinine ratio in those on dual therapy who switched from a tenofovir regimen

No changes from baseline in the CKD-EPI eGFR (cystatin C) in either arm

(n = 487)

(n = 484)

(n = 453)

(n = 455)

(n = 319)

(n = 325)

(n = 161)

(n = 174)

RBP (urine), nmol/L

β2M (urine), nmol/L

Change in Renal Markers

From Baseline to Week 48 Compared With CARSlide15

Inflammation Biomarkers: No Consistent Pattern in SWORD-1/-2 Pooled Data

*Baseline values are actual values.

Orkin C, et al. EACS 2017. Poster BPD2/10.

No consistent pattern

of change in atherogenesis

and inflammation markers from baseline to week 48 between dolutegravir plus rilpivirine and CAR

Biomarker

Type

Biomarker*

Week 48 Difference,

DTG + RPV − CAR (95% CI)

Inflammation

Hypercoagulability

Macrophage Activation

Monocyte Activation

Endothelial Dysfunction

Fatty Acid Metabolism

CRP, mg/L Baseline Week 48IL-6, ng/L Baseline Week 48

D-dimer, nmol/L FEU

Baseline

Week 48

sCD163, µg/L

Baseline

Week 48

sCD14, ng/mL

Baseline

Week 48

sVCAM-1,

µg/L

Baseline

Week 48

FABP2, ng/mL

Baseline

Week 48

−0.36

(−1.2, 1.0)

0.16

(−0.2, 0.4)

0.04

(−0.28, 0.34)

3.89

(−22.4, 206.3)

−359.06

(−451.7, 2325.5)

−66.00

(−190.8, 4180.9)

−0.66

(−0.9, 0.3)

Difference Between Week 48 and Baseline Effect on BiomarkersSlide16

Bone Turnover Biomarkers: Significant Decrease With Dual ART in Pooled SWORD-1/-2

Significantly greater decreases in bone turnover biomarkers in serum with dolutegravir plus rilpivirine vs CAR

Change From Baseline to Week 48

*

P

<.001

Orkin C, et al. EACS 2017. Poster BPD2/10.

Mean Serum

Concentration, μg/L

Mean Serum

Concentration, μg/L

Mean Serum

Concentration, μg/L

Mean Serum

Concentration, μg/LSlide17

Patient Factors: What to Consider When Making a Treatment Change

A thorough HIV treatment history is needed when choosing a new treatment

There may be a history of transmitted resistance or occurrence of virologic failure

A proviral DNA test can help identify current unknown treatments in virologically suppressed individuals

Any necessary time should be taken to gather all relevant information Slide18

Need for Treatment History: Clinical Case Example

The longer the patient has HIV, the longer and more complicated the treatment history

Treatment failure on

EFV/TDF/FTC

K103N mutation positive

(NNRTI resistance)

Failure on subsequent

line treatment

No longer K103N

mutation positive

New resistance test shows fully susceptible to NNRTI

What treatment do you choose?

Recent test indicates an NNRTI is an option

But treatment history indicates it may not be an optionSlide19

Assessing Comorbidities and Concomitant Medications

Comorbidities and concomitant treatments should be assessed when switching treatment

Even when the change is from a PI to a boosted PI

In patients with hepatitis B coinfection, need to consider treating both infections (eg, with an NRTI with activity against both)

A treatment switch has to include a regimen active against hepatitis B

In unvaccinated patients, it can increase protectionLifestyle of patient should be considered as treatment is long-termSlide20

Potential Reasons for Switching to Dual ART

There has to be a benefit when switching a patient's treatment

Address toxicity of the current therapy

Simplify a regimen (eg, if a patient is on a complex regimen)Slide21

a. European AIDS Clinical Society Guidelines 8.2. January 2017; b. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

Guidelines for Dual Therapy in Virologically Suppressed Individuals: EACS and HHS

EACS Guidelines

[a]

Dolutegravir + Rilpivirine

Lamivudine

Darunavir/

ritonavir

or

Darunavir/cobicistat Atazanavir/

ritonavir

or

Atazanavir/cobicistat

Dual

therapy

in patients

: a) without resistance to the PI; b) with viral

load suppression <50 copies/mL for at least the past 6 months; and c) absence of chronic HBV co-infectionHHS Guidelines[b]Dolutegravir + RilpivirineLamivudineAtazanavir /ritonavir orDarunavir /ritonavir orLopinavir/ritonavirLamivudine plus a ritonavir-boosted PI may be a reasonable option when the use of tenofovir, tenofovir alafenamide, or abacavir is contraindicated or not desirableDolutegravir + rilpivirine can be a reasonable option when the use of NRTIs is not desirable and when resistance to either compound is not expected++Slide22

a. Pérez-Molina JA, et al. EACS 2017. Abstract PS1/1; b. Di Giambenedetto S, et al.

J Antimicrob Chemother. 2017;72:1163-1171; c. Perez-Molina JA, et al. Lancet Infect Dis

. 2015;15:775-784; d. Arribas JR, et al.

Lancet Infect Dis

. 2015;15:785-792; e. Pulido F, et al. Clin Infect Dis. 2017. [Epub ahead of print]

Meta-Analysis of Switch to Dual Therapy TrialsMeta-analysis of individual patient data from 4 studies (N = 1051)[a]

Assess noninferiority of boosted PI plus lamivudine vs triple therapy using past and current FDA-established endpoints

(ie, a virologic failure noninferiority limit of 4%)

ATLAS-M

[b]

(n = 266)

SALT

[c]

(n = 286)

OLE

[d]

(n = 250)

DUAL

[e] (n = 249)Dual TherapyATV/r + LMVATV/r + LMVLPV/r + LMVDRV/r + LMVTriple Therapy ATV/r + 2 N(t)RTIsATV/r + 2 N(t)RTIsLPV/r + 2 N(t)RTIsDRV/r + 2 N(t)RTIsSlide23

Pérez-Molina JA, et al. EACS 2017. Abstract PS1/1.

Meta-Analysis: Primary Endpoint Results for Virologic Failure

At 48 weeks, 4% of patients on dual therapy vs 3.04% on triple therapy had HIV-RNA ≥50 copies/mL

Difference of 0.9% (95%CI: -1.3%, 3.2%)

Noninferiority margin: 4%

Favors

Dual

TherapySlide24

Pérez-Molina JA, et al. EACS 2017. Abstract PS1/1.

Secondary Endpoint: Change in Renal Function, Lipids, and CD4 Count

Variable

Dual Therapy Group

Triple Therapy Group

Difference

Dual vs Triple (95% CI)

CD4 cell

μ

/L

29.6

13.8

15.8 (-12.7, 44.3)

Total cholesterol

mg/dL

11.03

-1.66

12.6 (8.7, 16.5)

LDL mg/dL6.9-1.017.88 (4.47, 11.31)HDL mg/dL2.481.211.30 (-1.08, 3.69)Total cholesterol/HDL0.017-0.060.08 (-0.04, 0.20)Triglycerides mg/dL8.77

-4.75

13.54 (2.05, 25.02)

GFR mL/min

3.32

-1.89

5.24 (2.90, 7.58)

Change from baseline to week 48

With dual therapy, there was an improvement in eGFR and worsening of lipid levels vs triple therapySlide25

Continuous Viral Load Suppression With Dual ART: DUAL-GESIDA Trial

Pulido F, et al.

Clin Infect Dis

. 2017. [Epub ahead of print]

Trial evaluating noninferiority of dual therapy with darunavir/ritonavir and lamivudine vs triple therapy with darunavir/ritonavir plus 2 NRTIs for maintenance of HIV-1 suppression

Viral load blips were similar between the dual-therapy group (14/126) and the

triple-therapy group (17/123)

Difference: 1.2%;

95% CI: -7.8, 10.1Slide26

Pulido F, et al.

Clin Infect Dis. 2017. [Epub ahead of print]

Virologic Failures Without Resistance:

DUAL-GESIDA Trial

Resistance testing attempted in every sample with viral load >400 copies/mL

Results confirmed that dual therapy with a boosted PI was not associated with a higher risk of developing lamivudine resistance

Results

Dual Therapy

Triple Therapy

Number of

patients with

a viral load >400 copies/mL during the study

Number with virologic

failure

3

2

2

0

Mutation test resultWild-type virus in 2 patientsL10I, A71T, and L76W mutations in the protease gene in 1 sampleResistance test resultNASusceptible to DRVNegative resistance test for M184V mutation to lamivudineSlide27

Pérez-Molina JA, et al. EACS 2017. Abstract PS1/1.

European AIDS Clinical Society Guidelines 8.2. January 2017.

US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

Evidence for Dual ART: Conclusions

A meta-analysis of 4 trials of dual vs triple therapy confirm that a boosted PI plus lamivudine is effective in maintaining virologic suppression

[a]EACS and HHS guidelines include these dual therapies as potential switching strategies in patients meeting criteria for suppression

[b,c] Slide28

Patient Management: Need for Monitoring

The studies of dual therapy had monitoring at similar endpoints and had similar outcomes

Regimens were noninferior to triple therapy or previous regimen

More frequent monitoring will depend on the regimens involved in the switch

Eg, if the switch is to 2 new regimens for the patient, then monitoring for emerging AEs will be requiredSlide29

Adverse Events Leading to Withdrawal

or Discontinuation: SWORD-1/-2

NNRTI

PI

INSTI

Adverse

Event, n (%)

DTG + RPV

(n = 275)

CAR

(n = 278)

DTG + RPV

(n = 133)

CAR

(n = 136)

DTG + RPV

(n = 105)

CAR

(n = 97)Any 8 (3)1 (<1)7 (5)2 (1)6 (6)0GI2 (<1)0

3 (2)

0

2 (2)

0

Nervous system

1 (<

1)

0

0

0

1 (<

1)

0

Psychiatric

4 (1)

1 (<

1)

3 (2)

0

2 (2)

0

Neoplasms

0

0

2(2)

2 (1)

1 (<

1)

0

Respiratory/thoracic/

mediastinal

0

0

1 (<

1)

0

1 (<

1)

0

Hepatobiliary

1 (<

1)

0

0

0

0

0

Summary of AEs by baseline ART third-agent class

Discontinuations were low at 3% in those switching from an NNRTI

Orkin C, et al. EACS 2017. Poster BPD1/5.Slide30

Dual ART: Other Considerations

May save costs to the health system or patients compared with triple therapy

No need for increased monitoring

In case of dual regimen boosted PI plus lamivudine or dolutegravir plus rilpivirine

Warn patient of possible AEs at the beginning

Still requires need to remind patients to adhere strictly to regimenSlide31

Concluding Remarks

Dual therapy is emerging as a viable strategy

Not yet first line

In virologically suppressed patients

In patients with good treatment history and genetic susceptibility

Two regimens can be proposedBoosted PI plus lamivudineDolutegravir plus rilpivirineNeed to select patients correctly and advise them to return if they experience any emerging AEs

Need to take into account ART history

Follow-up still neededSlide32

Concluding Remarks (cont)

Do not forget the protection against hepatitis B and the need for hepatitis B therapy

Do not forget the inclusion criteria for the switch studies:

Patients who are very stable, have had undetectable viral load for at least 6 months, and have high adherence

Take your time in selecting patients and review each patient's history

This era of ART provides many options for well-selected patientsSlide33

To proceed to the online CME test, click on the

Earn CME Credit

link on this page.

Thank you for participating in this activity.